Plasma glycated CD59 (gCD59), a novel biomarker for the diagnosis, management and follow up of women with Gestational Diabetes (GDM) – protocol for prospective cohort study

BACKGROUND: The prevalence of Gestational Diabetes (GDM) is rising and with it the number of mothers and children at risk of adverse outcomes. As treatment has been shown to reduce adverse events, it is imperative that we identify all at-risk pregnant women. In Ireland, the national standard of care...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogdanet, D., O’Shea, PM., Halperin, J., Dunne, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368790/
https://www.ncbi.nlm.nih.gov/pubmed/32682411
http://dx.doi.org/10.1186/s12884-020-03090-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368790/
https://www.ncbi.nlm.nih.gov/pubmed/32682411
http://dx.doi.org/10.1186/s12884-020-03090-9

Ejemplares similares